Cilengitide
Phase 2UNKNOWN 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Newly Diagnosed Non Methylated Glioblastoma Multiforme Grade 4
Conditions
Newly Diagnosed Non Methylated Glioblastoma Multiforme Grade 4
Trial Timeline
Nov 1, 2009 → Jan 1, 2014
NCT ID
NCT01124240About Cilengitide
Cilengitide is a phase 2 stage product being developed by Merck for Newly Diagnosed Non Methylated Glioblastoma Multiforme Grade 4. The current trial status is unknown. This product is registered under clinical trial identifier NCT01124240. Target conditions include Newly Diagnosed Non Methylated Glioblastoma Multiforme Grade 4.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01124240 | Phase 2 | UNKNOWN |
Competing Products
18 competing products in Newly Diagnosed Non Methylated Glioblastoma Multiforme Grade 4